Abstract
Since the inception of the Medicare End Stage Renal Disease Program in 1972, the medical director has been an important leader in the dialysis unit. The initial duties of the medical director were focused on quality and safety but were gradually expanded over the decades to include the development and oversight of protocols to manage metabolic bone disease and anemia. As the total cost of ESRD care has escalated, there have been progressive attempts to control costs through additional bundling and the creation of alternative payment schemes. While we await the financial and clinical outcomes of these initiatives, the medical director's role continues to expand in scope and now includes an enhanced role for not only clinical outcomes but financial outcomes as well.
Original language | English |
---|---|
Pages (from-to) | 177-182 |
Number of pages | 6 |
Journal | Seminars in Dialysis |
Volume | 31 |
Issue number | 2 |
DOIs | |
State | Published - Mar 1 2018 |